Skip to main content
Publications
Neal J, Lee JB, Ahn MJ, Ariyasu R, nash C, Smith D, Nagar S, Jimenez M, Kahangire DA, Kim YJ, Nasirova F, Lin S. Treatment (tx) patterns and clinical outcomes in unresectable stage III epidermal growth factor receptor-mutation positive (EGFRm) non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT): interim analysis of a global real-world (RW) study. Poster presented at the European Lung Cancer Congress (ELCC) 2024; March 20, 2024. Prague, Czech Republic.
Lin S, Kahangire DA, Nagar S, Ahn M, Affi R, Agulnik J, Shih J, Hockmair MJ, Tufman A, Debieuvre D, Chow J, Jimenez M, Davis KL, Sandelin M, Veluswamy R. Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study. Poster presented at the European Lung Cancer Congress 2023; March 31, 2023. Copenhagen, Demark.
Simmons DJ, Blank SV, Nagar S, Nham T, Long GH, Davis KL, Wetherill G, Munley J, McLaurin K. Real-world evaluation of PARP inhibitor tolerability in advanced ovarian cancer: retrospective US cohort study. Poster presented at the SGO 2023 Annual Meeting on Women's Cancer; March 27, 2023. Tampa, FL.
Shih JY, Lin SH, Nagar SP, Davis KL, Jimenez MI, Kahangire DA, Servidio L, Ho L, Veluswamy R. Treatment patterns in resectable early-stage NSCLC in Taiwan: subgroup analysis of a global real-world study. Poster presented at the 2022 ESMO Asia Congress; December 2, 2022. Singapore, Republic of Singapor.
Veluswamy R, Ahn MJ, Nagar S, Affi R, Agulnik J, Shih JY, Hochmair MJ, Tufman A, Debieuvre D, Jimenez MI, Davis K, Kahangire DA, Servidio L, di Perna C, Lin SH. Surgical resection, treatment patterns and outcomes in patients (pts) with early-stage non-small cell lung cancer (NSCLC): interim analysis of a global real-world study. Poster presented at the 2022 International Thoracic Surgical Oncology Summit; September 30, 2022. New York, NY.
Lin SH, Ahn M, Nagar S, Affi R, Agulnik J, Shih J, Hochmair MJ, Tufman A, Debieuvre D, Jimenez MI, Davis K, Kahangire DA, Servidio L, Veluswamy R. Treatment patterns and outcomes in resectable early stage NSCLC: interim analysis of a global real-world study. Poster presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2022. Chicago, IL.
Shah R, Girard N, Nagar S, Griesinger F, Roeper J, Davis KL, Bakker NA, Thakrar B, Taylor A, Feliciano J. Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI). Poster presented at the ESMO 2019 Congress; September 27, 2019. Barcelona, Spain.
Saif W, Parikh R, Ray D, Kaye JA, Kurosky S, Thomas S, Halfdanarson T, Beveridge T, Mirakhur B, Lubeck CA, Nagar SP, Soares H. The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Poster presented at the NANETS Regional NET Education Conference; September 15, 2018. New Brunswick, NJ. Previously presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Kajinami K, Nagar SP, Meyers J, Rane PP, Davis K, Fox KM, Beaubrun A, Inomata H, Qian Y. Treatment utilization patterns and possible statin intolerance among high-risk patients in a real-world Japanese population. Poster presented at the 81st Annual Scientific Meeting of the Japanese Circulation Society; March 19, 2017. Kanazawa, Japan.
Goyal RK, Carter GC, Nagar SP, Smyth EN, Price GL, Huang Y-J, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Treatment patterns and resource utilization among patients with HR+/HER2– metastatic breast cancer in a privately insured US population. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 9, 2016. San Antonio, TX.
Goyal RK, Carter GC, Nagar SP, Smyth EN, Price GL, Huang Y-J, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2– metastatic breast cancer. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 9, 2016. San Antonio, TX.